Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

in response to

Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

BearDownAZ

posted on Oct 18, 2019 12:56PM

Study site locations now recruiting are up to 6; 5 in US, 1 in Belgium as of the Sept 10th 2019 ClinicalTrials.gov update.